2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on …

PA Heidenreich, B Bozkurt, D Aguilar, LA Allen… - Journal of the American …, 2022 - jacc.org
Abstract Aim The “2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure”
replaces the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the …

Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities

TK Kim, EN Vandsemb, RS Herbst… - Nature Reviews Drug …, 2022 - nature.com
Tumours employ various tactics to adapt and eventually resist immune attack. These
mechanisms are collectively called adaptive immune resistance (AIR). The first defined and …

Rational combinations of targeted cancer therapies: background, advances and challenges

H Jin, L Wang, R Bernards - Nature Reviews Drug Discovery, 2023 - nature.com
Over the past two decades, elucidation of the genetic defects that underlie cancer has
resulted in a plethora of novel targeted cancer drugs. Although these agents can initially be …

[HTML][HTML] Signal pathways of melanoma and targeted therapy

W Guo, H Wang, C Li - Signal transduction and targeted therapy, 2021 - nature.com
Melanoma is the most lethal skin cancer that originates from the malignant transformation of
melanocytes. Although melanoma has long been regarded as a cancerous malignancy with …

[HTML][HTML] Clinical cancer immunotherapy: Current progress and prospects

C Liu, M Yang, D Zhang, M Chen, D Zhu - Frontiers in immunology, 2022 - frontiersin.org
Immune checkpoint therapy via PD-1 antibodies has shown exciting clinical value and
robust therapeutic potential in clinical practice. It can significantly improve progression-free …

[HTML][HTML] Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study

V Subbiah, RJ Kreitman, ZA Wainberg, JY Cho… - Annals of …, 2022 - Elsevier
Background Combined therapy with dabrafenib plus trametinib was approved in several
countries for treatment of BRAF V600E-mutant anaplastic thyroid cancer (ATC) based on an …

[HTML][HTML] The MAPK and AMPK signalings: interplay and implication in targeted cancer therapy

J Yuan, X Dong, J Yap, J Hu - Journal of hematology & oncology, 2020 - Springer
Cancer is characterized as a complex disease caused by coordinated alterations of multiple
signaling pathways. The Ras/RAF/MEK/ERK (MAPK) signaling is one of the best-defined …

Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three …

PA Ascierto, M Mandalà, PF Ferrucci… - Journal of Clinical …, 2023 - ascopubs.org
PURPOSE Limited prospective data are available on sequential immunotherapy and
BRAF/MEK inhibition for BRAFV600-mutant metastatic melanoma. METHODS SECOMBIT is …

Challenges and opportunities in cancer drug resistance

RA Ward, S Fawell, N Floc'h, V Flemington… - Chemical …, 2020 - ACS Publications
There has been huge progress in the discovery of targeted cancer therapies in recent years.
However, even for the most successful and impactful cancer drugs which have been …

[HTML][HTML] Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies

ME Bahar, HJ Kim, DR Kim - Signal transduction and targeted therapy, 2023 - nature.com
Metastatic dissemination of solid tumors, a leading cause of cancer-related mortality,
underscores the urgent need for enhanced insights into the molecular and cellular …